Hematopoiesis News Volume 1.42 | Nov 2 2010

    By
    Justin.choi
    -
    0
    29

    Hematopoiesis News 1.42, November 2, 2010.  
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe

    TOP STORY

    Study Identifies Key Molecules In Multiple Myeloma  ShareThis
    New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood. [Press release from The Ohio State University Medical Center discussing online prepublication in Cancer Cell]

    MethoCult® Express: Request A Sample 
    Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express
    by STEMCELL Technologies
    		 
     
    REQUEST A SAMPLESTEMCELL Technologies Inc
    		 

    SPECIAL FEATURE

    Georges Mathé, a Founder of Bone Marrow Transplantation, Dies at Age 88
    Georges Mathé died this month at the age of 88. He was a compassionate physician and a brilliant scientist with an original mind who will be remembered as a founding father of stem cell transplantation. [The American Society for Blood and Marrow Transplantation Press Release]

    Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at info@connexoncreative.com

    Follow us on Twitter! @Hema_News

    SCIENCE NEWS

    Mount Sinai Researchers Make Groundbreaking Discovery on Origin of Brain’s Immune Cells
    Researchers have shown that hematopoietic precursor cells develop into microglia only during a short period after conception. [Press release from the Mount Sinai Medical Center discussing online prepublication in Science]

    Researchers Tap New Source of Cancer Markers in Blood
    Scientists report on a new source of blood-derived biomarkers that could soon help doctors determine whether a recovering cancer patient has relapsed, and may someday aid in the early detection of a variety of cancers. [Press release from the American Technion Society discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

    Watch Procedure Now 
    Further Improve Hematopoietic Progenitor Proliferation
    with Human LDL
    by STEMCELL Technologies
    		 
     
    ORDER NOWSTEMCELL Technologies Inc
    		 

    CURRENT PUBLICATIONS  (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
    Researchers show that postnatal hematopoietic progenitors do not significantly contribute to microglia homeostasis in the adult brain. [Science]

    RNA-Seq Analysis of Two Closely Related Leukemia Clones that Differ in Their Self-Renewal Capacity
    The results provide the first comprehensive transcriptome analysis of a leukemia stem cell and document an unexpected level of transcriptome variation between phenotypically similar leukemic cells. [Blood]

    Hoxa3 Promotes the Differentiation of Hematopoietic Progenitor Cells into Proangiogenic Gr-1+CD11b+ Myeloid Cells
    Here, researchers show that sustained expression of Hoxa3 in diabetic-derived bone marrow-derived Gr-1+CD11b+ cells reverses their ‘diabetic’ phenotype. These findings demonstrate that manipulation of adult stem/progenitor cells ex vivo could be used as a potential therapy in patients with impaired wound healing. [Blood]

    Hematopoietic Differentiation of Induced Pluripotent Stem Cells from Patients with Mucopolysaccharidosis Type I (Hurler Syndrome)
    Researchers generated induced pluripotent stem cells from two patients with mucopolysaccharidosis type I (MPS-iPS cells). They found that alpha-L-iduronidase was not required for stem cell renewal, MPS-iPS cells showed lysosomal storage characteristic of mucopolysaccharidosis type I, and could be differentiated to both hematopoietic and non-hematopoietic cells. [Blood]

    Soluble Plasma HLA Peptidome as a Potential Source for Cancer Biomarkers
    Although low levels of soluble HLA molecules (sHLA) are normally released into the blood, many types of tumor cells release larger amounts of these sHLA molecules, presumably to counter immune surveillance by T cells. Here, researchers demonstrate that these sHLA molecules are still bound with their authentic peptide repertoires, similar to those of the membranal HLA molecules. [Proc Natl Acad Sci USA]

    Pre-B Cell Leukemias in Btk/Slp65-Deficient Mice Arise Independently of Ongoing V(D)J Recombination Activity
    In this report, researchers investigated whether Rag-induced DNA damage is involved in oncogenic transformation of Slp65-deficient B cells. [Leukemia]

    PHF6 Mutations in Adult Acute Myeloid Leukemia
    The results identify PHF6 as a tumor suppressor gene mutated in acute myeloid leukemias and extend the role of this X-linked tumor suppressor gene in the pathogenesis of hematologic tumors. [Leukemia]

    CLINICAL RESEARCH

    Predictive Factors for Outcome and Response in Patients Treated with Second Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia in Chronic Phase Post Imatinib Failure
    Researchers assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second generation tyrosine kinase inhibitors after imatinib failure. [Blood]

    Promoter Polymorphisms in the Beta-2 Adrenergic Receptor are Associated With Drug-Induced Gene Expression Changes and Response in Acute Lymphoblastic Leukemia
    Researchers investigated whether genetic polymorphisms in the promoter region of the proapoptotic beta-2 adrenergic receptor gene (ADRB2) influence treatment-induced changes in ADRB2 expression in leukemia cells and response to chemotherapy. [Clin Pharmacol Ther]


    INDUSTRY NEWS

    EpiCept Corporation and FDA Agree on Development Plan for Ceplene®
    EpiCept Corporation announced that it has reached an agreement on all outstanding issues with the U.S. Food and Drug Administration on a regulatory path forward for Ceplene(R) (histamine dihydrochloride), the Company’s lead product for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia in first complete remission. [EpiCept Corporation Press Release]

    FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
    After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. [Bristol-Myers Squibb Company Press Release]

    Celator(R) Pharmaceuticals Completes Enrollment in a Second Phase II Trial of CPX-351 In Acute Myeloid Leukemia
    Celator Pharmaceuticals announced that it has completed enrollment in a phase II multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia in first relapse. [Celator Pharmaceuticals, Inc. Press Release]

    POLICY NEWS

    NIH Introduces Images, a Database of Images in Biomedical Literature
    More than 2.5 million images and figures from medical and life sciences journals are now available through Images, a new resource for finding images in biomedical literature. [National Institutes of Health, United States]

    NIH Recovery Act Grants to Foster Scientific Workforce Diversity
    The National Institutes of Health has awarded six grants totaling approximately $12 million over three years through a new initiative aimed at fostering a diverse scientific workforce. [National Institutes of Health, United States]

    Guidelines for Use of Stored Specimens and Access to Ancillary Data and Proposed Cost Schedule: Stored Biologic Specimens and Ancillary Data From the Collaborative Perinatal Project (CPP) (FR Doc. 2010-27183) [National Institutes of Health, United States]

    National Heart, Lung, and Blood Institute; Notice of Closed Meetings (FR Doc. 2010-27319) [National Institutes of Health, United States]

    National Heart, Lung, and Blood Institute; Notice of Meetings (FR Doc. 2010-27318) [National Institutes of Health, United States]

    National Heart, Lung, and Blood Institute; Notice of Closed Meeting (FR Doc. 2010-26889) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-27325) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-27185) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-27192) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-27039) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-27040) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-27049) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26881) [National Institutes of Health, United States]

    Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-26935) [National Institutes of Health, United States]

    National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-27410) [National Institutes of Health, United States]

    Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-27187) [National Institutes of Health, United States]

    EVENTS (Listed by Date)

    9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
    November 7-10, 2010
    Philadelphia, United States

    22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
    November 16-19, 2010
    Berlin, Germany

    9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
    November 17-19, 2010
    Sonoma, United States

    52nd American Society of Hematology (ASH) Annual Meeting and Exposition
    December 4-7, 2010
    Orlando, United States

    5th Annual Stem Cell Meeting on the Mesa
    December 7, 2010
    La Jolla, United States

    Highlights of American Society of Hematology (ASH) Vancouver
    January 21-22, 2011
    Vancouver, Canada

    Highlights of American Society of Hematology (ASH) Washington, D.C.
    January 28-29, 2011
    Washington, D.C., United States

    Highlights of American Society of Hematology (ASH) San Francisco
    January 28-29, 2011
    San Francisco, United States

    Highlights of American Society of Hematology (ASH) New York
    February 4-5, 2011
    New York, United States

    Highlights of American Society of Hematology (ASH) San Diego
    February 4-5, 2011
    San Diego, United States

    BMT Tandem Meetings (ASBMT/CIBMTR)
    February 17-21, 2011
    Honolulu, Hawaii

    Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
    February 23-25, 2011
    San Francisco, United States

    American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
    March 3-6, 2011
    Vancouver, Canada

    Keystone Symposia: Hematopoiesis
    March 27-April 1, 2011
    Big Sky, United States

    United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
    March 30-April 1, 2011
    York, United Kingdom

    American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
    April 2-6, 2011
    Orlando, United States

    37th Annual Meeting of the European Group for Blood and Marrow Transplantation
    April 3-6, 2011
    Paris, France

    International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
    June 15-18, 2011
    Toronto, Canada

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

    JOB OPPORTUNITIES

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

    Business Manager – Centre for Blood Cell Therapies (Cell Therapies)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

    Visit  here to post your career opportunities.


    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!



    Comments or Suggestions? Email info@connexoncreative.com with your feedback.


    Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us